Lifespan Vision Ventures invests in Bolden Therapeutics
Summary
This biotechnology company is developing first-in-class therapeutics to promote neurogenesis for the potential treatment of central nervous system diseases.Andrew Worden, Founding Partner at LifeSpan Vision Ventures, stated: Were excited to partner with Bolden Therapeutics and enthusiastic about the potential of their promising results in advancing treatment options for Alzheimers disease and other age-related neurodegenerative conditions. The companys scientific co-founders, Dr. Justin Fallon and Dr. Ashley Webb have identified a key molecular pathway to stimulate neural stem cells to promote the birth of new neurons (neurogenesis) in the adult brain. The company is currently working on antisense oligonucleotides for this genetically validated target, with candidates ready for in vivo efficacy testing.Boldens research facilities are based within Tufts Launchpad | biolabs, a leading incubator for next-generation powerhouse biotech startups located in Boston, MA. Our mission is to support and accelerate the development of innovative therapies that extend healthspan, improve the quality of life for individuals as they age, and address age-related challenges. Through strategic partnerships and investments, we aim to shape a future where aging is met with vitality, resilience, and endless possibilities.For more information, please visit: https://www.lifespanvisionventures.com/